

CRT-2016

International Conference on
**Cancer Research and
Targeted Therapy**

**21-23
October
2016**

Venue
Holiday Inn Inner
Harbor-
Baltimore Downtown
MD, USA



- 08:00-08:30 **Registrations**
- 08:30-08:40 **Introduction to CRT-2016**
- 08:45-14:45 **Keynote Session** @ Chesapeake
- 08:45-09:15 **Novel Strategies for Checkpoint Blockade Inhibition: Targeting CD39 Ectonucleotidase and Correcting Aberrant Purinergic Signaling in Cancer**
Simon Robson, Harvard Medical School, MA, USA
- 09:15-09:45 **miRNAs at Cell-Cell Junctions: Role in Cancer and Implications for Therapy**
Panos Z. Anastasiadis, Mayo Clinic, FL, USA
- 09:45-10:15 **The ACTION Study: an Initiative to Address the Socio-Economic Burden of Cancer in South-East Asia**
Mark Woodward, University of Oxford, UK
- 10:15-10:45 **JAK/STAT Abnormalities in T-Cell Malignancy: Implications for Therapy**
Thomas Waldmann, NIH/NCI, MD, USA
- 10:45-11:00 **Coffee Break** @ Chesapeake Foyer
- 11:00-11:30 **Molecular Targeting for Brain Tumors Treatment**
Waldemar Debinski, Wake Forest School of Medicine, NC, USA
- 11:30-12:00 **Targeting the Unfolded Protein Response to Overcome Therapeutic Resistance in Cancer**
Hari K. Koul, Feist-Weiller Cancer Center, LA, USA
- 12:00-12:30 **Pre-clinical Vetting of Novel Treatment Strategies for Brain Tumors Using PDX Models**
Sarkaria Jann N, Mayo Clinic, Minn, USA
- 12:30-13:00 **The Danger Model on Immunotherapy**
Polly Matzinger, NIH/NIAID, MD, USA
- 13:00-13:45 **Lunch Break** @ Chesapeake Foyer
- 13:45-14:15 **Cancer Cigarette Smoke and the 18 kDa Translocator Protein TSPO**
Rafi Nagler, Rambam Health Care Campus, Israel
- 14:15-14:45 **Glioblastoma Heterogeneity Modelling *in-vitro* and *in-vivo***
Tamara Lah Turnsek, National Institute of Biology, Ljubljana, Slovenia

Special Talk

- 14:45-15:15 **The Role of Zinc in the Development of Cancers and its Implications for Treatment and Prevention**
Leslie C. Costello, University of Maryland Greenebaum Cancer Center, MD, USA
Renty Franklin, University of Maryland Greenebaum Cancer Center, MD, USA

15:15-15:45 **Plant Extracted Solasodine Rhamnosides, a New Era for Cancer Therapy?**
Bill Cham, Australasian Institute of Medical Research, Vanuatu

15:45-16:00 **Coffee Break**

@ Chesapeake Foyer

16:00-18:40 **Novel Therapies in Cancer Treatment**

Featured Presentations

Session Chairs **Myron Szewczuk**, Queen's University, Canada
Srikumar P. Chellappan, H. Lee Moffitt Cancer Center and Research Institute, FL, USA

16:00-16:20 **Lung Cancer Stemness and Metastasis: Novel Mechanisms and Therapeutic Targets**
Srikumar P. Chellappan, H. Lee Moffitt Cancer Center and Research Institute, FL, USA

16:20-16:40 **Effects of Anticancer Drug on Chromosome Instability (CIN) and New Clinical Implications for Tumor-Suppressing Therapies**
Liskovykh Mikhail, NIH/NCI, MD, USA

16:40-17:00 **Application of a Subclass of Camptothecin Analogues with Novel Mechanism of Action for Targeted and Personalized Cancer Treatment**
Fengzhi Li, Roswell Park Cancer Institute, NY, USA

17:00-17:20 **New Therapeutic Delivery Approaches in Neuro-oncology**
Graeme Woodworth, University of Maryland School of Medicine, MD, USA

17:20-17:40 **Discovery of a Novel Therapeutic Target in Multistage Tumorigenesis**
Myron Szewczuk, Queen's University, Canada

17:40-18:00 **A Novel β -Catenin Signaling Pathway Activated by Interleukin 1 β Leads to the Onset of Epithelial-Mesenchymal Transition in Breast Cancer Cells and Drug Resistance**
Isaura Meza, Centro de Investigaci3n y de Estudios Avanzados del IPN, Mexico

18:00-18:20 **Identification of Novel Cancer-Relevant PARP1 Inhibitor Targets by Chemical Proteomics**
Uwe Rix, H. Lee Moffitt Cancer Center & Research Institute, FL, USA

18:20-18:40 **Targeting FGFR1 in Non Hodgkins Lymphoma**
Lalit Sehgal, UT MD Anderson Cancer Center, TX, United States

08:00-12:40	Tumor Suppressors Cancer Immunotherapy and Vaccines	Featured Presentations
Session Chairs	Thomas Waldmann, NIH/NCI, MD, USA Mariusz Wasik, University of Pennsylvania, PA, USA	
08:00-08:20	IL-15 in the Life and Death of Lymphocytes: Implications for the Treatment of Cancer Thomas Waldmann, NIH/NCI, MD, USA	
08:20-08:40	Targeting Immune Suppression in the Cancer Microenvironment Dennis Klinman, NIH/NCI, MD, USA	
08:40-09:00	A Role of IL-18 and Innate Immune Cells in Cancer Immunotherapy Haruki Okamura, Hyogo College of Medicine, Hirakata-City, Japan	
09:00-09:20	Combination of CART19 Immunotherapy with Inhibition of BTK, B-cell-expressed Kinase, in Lymphoma Mariusz Wasik, University of Pennsylvania, PA, USA	
09:20-09:40	Use of Dual-Mode Cellular Imaging in Cancer Vaccine Development Jeff Bulte, Johns Hopkins University School of Medicine, MD, USA	
09:40-10:00	Beyond Immune Checkpoint: First-in-Class Antibody Targeting Soluble NKG2D Ligand sMIC for Cancer Immunotherapy Jennifer D. Wu, Medical University of South Carolina, SC, USA	
10:00-10:20	Discovery and Optimization of OICR9429: An Antagonist of the WDR5 and MLL1 Interaction Rima Al-Awar, Ontario Institute for Cancer Research, Canada	
10:20-10:40	Coffe Break	@ Chesapeake Foyer
10:40-11:00	Tumor Microenvironment: Promising Target of Successful Anticancer Therapy Pavol Szabo, Charles University in Prague, Czech Republic	
11:00-11:20	How Cancer Cells Program the Tumor Microenvironment of Pancreatic Cancer Lei Zheng, Johns Hopkins School of Medicine, MD, USA	
11:20-11:40	Neoadjuvant Immunotherapy in High Risk Melanoma: A New Justified Approach E. George Elias, University of Maryland, MD, USA	
11:40-12:00	Nano-Diamino-Tetrac (Nanotetrac, NDAT), a Thyroid Hormone Antagonist at Integrin avb3, Causes Necrosis via Anti-angiogenesis and Induces Apoptosis in Human Glioblastoma Xenografts Paul J Davis, Albany College of Pharmacy and Health Sciences, Albany, NY, USA	
12:00-12:20	NOSH-NSAIDs a New Class of Anti-Inflammatory Pharmaceuticals as Chemotherapeutic Agents Khosrow Kashfi, City University of New York School of Medicine, NY, USA	

- 12:20-12:40 **Anti-Cancer Chemotherapy Specific to Acidic Cancer Nests**
Hiroshi Kobayashi, Chiba University, Japan
- 12:40-13:40 **Lunch Break** @ Chesapeake Foyer
- 13:40-18:00 **Special Session: Anti-cancer Drug Discovery from Mother Nature**
- Session Chair **Anupam Bishayee**, Larkin Health Sciences Institute, FL, USA
- 13:40-14:00 **Session Introduction**
Inauguration of Journal of Natural Products in Cancer Prevention and Therapy
- 14:00-14:20 **Prevention of Mammary Carcinogenesis by *Trianthema portulacastrum*: Preclinical Evidence and Molecular Mechanisms**
Anupam Bishayee, Larkin Health Sciences Institute, FL, USA
- 14:20-14:40 **Paradigm for Natural Product-Based Medicinal Discovery and Recent Innovations**
Steven J. Melnick, Nicklaus Children's Hospital, FL, USA
- 14:40-15:00 **Anti-cancer Activity of Fisetin, a Flavonoid from Mother Nature**
Hasan Mukhtar, University of Wisconsin, WI, USA
- 15:00-15:20 **Tea Polyphenols as Modulators of Nrf2: Implication in Chemoprevention and Chemotherapeutics**
Dona Sinha, Chittaranjan National Cancer Institute, WB, India
- 15:20-15:40 **Coffee Break** @ Chesapeake Foyer
- 15:40-16:00 **Novel VEGFR2 Inhibitors for Treating Solid Tumors and Brain Metastasis**
Appu Rathinavelu, Nova Southeastern University, FL, USA
- 16:00-16:20 **Bitter Melon's Sweet Promise: Role in Head and Neck Cancer**
Ratna B. Ray, Saint Louis University, MO, USA
- 16:20-16:40 **Importance of the Integration of African Traditional Medicine into the Existing Health Care System for Inflammatory Diseases and Cancer**
Kensese S. Mossanda, Walter Sisulu University, South Africa
- 16:40-17:00 **Targeting Ubiquitin Proteasome System with Natural Compounds: Implications in Anti-cancer Therapy**
Rahul R. Deshmukh, LECOM School of Pharmacy, PA, USA
- 17:00-17:20 **Resveratrol-copper: A Novel Extracellular DNA-degrading Agent in the Treatment of Cancer**
Indraneel Mitra, Tata Memorial Centre, MH, India
- 17:20-17:40 **Bioactives from *Cinnamomum tamala* with Potential Antitumor Role**
Archana R Juvekar, Institute of Chemical Technology, MH, India
- 17:40-18:00 **Resveratrol Driven Suicide Gene Therapy for Non Small Cell Carcinoma**
Deepak Bhatia, Shenandoah University, VA, USA

Breakout-II

@ Harbor IA

08:00-11:40 Cancer Metastasis

- Session Chairs **Maria Kukuruzinska**, Boston University, MA, USA
Gunnar Boysen, University of Arkansas for Medical Sciences, AR, USA
- 08:00-08:20 **Intratumor Heterogeneity in Human Tumors: Beyond the Genes**
Santiago Ramon Y Cajal, Universidad Autonoma of Barcelona, Spain
- 08:20-08:40 **Neuropeptides as Autocrine Growth Factors in Lung Cancer**
Terry Moody, NIH/NCI, MD, USA
- Targeted Therapies for Pediatric Cancers**
- 08:40-09:00 Anthony C Faber, Virginia Commonwealth University, Massey Cancer Center and School of Dentistry, VA, USA
- 09:00-09:20 **Interaction Between ZBP-89 and Oncogenic Molecules in Hepatocellular Carcinoma**
George G Chen, The Chinese University of Hong Kong, China
- 09:20-09:40 **Extra-Cellular Ubiquitin: Relevance in Understanding Hematological Cancers**
Krishnamoorthy Kannan, GGS Indraprastha University, Delhi, India
- 09:40-10:00 **Targeting the Wnt/beta-catenin-N-glycosylation Axis in Head and Neck Cancer**
Maria Kukuruzinska, Boston University, MA, USA
- 10:00-10:20 **Coffee Break** @ Chesapeake Foyer
- 10:20-10:40 **Dendrimer-Based Proteostasis-Inhibition Strategy to Control NSCLC Progression and Metastasis**
Neeraj Vij, Central Michigan University, MI, USA
- 10:40-11:00 **Astrocytes Promote Brain Metastases of Breast Cancer via Induction of Autophagy**
Ilya Ulasov, Swedish Medical Center, WA, USA
- 11:00-11:20 **Diagnosis of Lung Tumor Types Based on Metabolomic Profiles in Lymph Node Aspirates**
Gunnar Boysen, University of Arkansas for Medical Sciences, AR, USA
- 11:20-11:40 **Using Gene Editing to Investigate the Role of MicroRNA and RNA Splicing in Cancer**
Ren Jang Lin, City of Hope, CA, USA

11:40-16:40 Cancer Cell Biology

- Session Chairs **David Wink**, NIH/NCI, MD, USA
Susanne Gabrielsson, Karolinska Institutet, Sweden
- 11:40-12:00 **Dendritic Cell Derived Exosomes for Cancer Therapy**
Susanne Gabrielsson, Karolinska Institutet, Sweden
- 12:00-12:20 **KRAS: Signaling and Cancer**
Ruth Nussinov, NIH/NCI, MD, USA

- 12:20-12:40 **The Oncogenic Properties of the Redox Inflammatory Protein Inducible Nitric Oxide Synthase in ER(-) Breast Cancer. Development of Models for Poor Outcome**
David Wink, NIH/NCI, MD, USA
- 12:40-13:00 **Tumor-Targeting with Antibody-Based Agents**
David Fitz Gerald, NIH/NCI, MD, USA
- 13:00-14:00 **Lunch Break** @ Chesapeake Foyer
- 14:00-14:20 **Optimizing Therapeutic Strategies for Lung Cancer Treatment by Targeting Mitochondrial and Heme Function**
Li Zhang, The University of Texas at Dallas, TX, USA
- 14:20-14:40 **Dietary Nutrients Induced Epigenetic Changes in Triple Negative Breast Cancer**
Asha Lakshmikuttyamma, Thomas Jefferson University, PA, USA
- 14:40-15:00 **Single Cell Heterogeneity in Response to Therapy**
Guido Lenz, Center of Biotechnology, UFRGS, Brazil
- 15:00-15:20 **Signaling of Oncogenic K-Ras Through Calmodulin**
Vadim Gaponenko, University of IL at Chicago, IL, USA
- 15:20-15:40 **Regulation of ABC Transporters by COX2: Potential use of Celecoxib in MDR Cancers**
Arunasree M Kalle, University of Hyderabad, TS, India
- 15:40-16:00 **Oxidative Stress-Induced Sulfiredoxin Promotes Colorectal Cancer Development**
Qiou Wei, University of Kentucky, KY, USA
- 16:00-16:20 **Hypoxia-Inducible Factors in Cancer Stem Cells and Inflammation: Implications in Leukemia Therapy**
Yang Liu, Children's National Medical Center, Washington DC, USA
- 16:20-16:40 **Augmented Telomerase Activity, Reduced Telomere Length and the Presence of Alternative Lengthening of Telomere in Renal Cell Carcinoma: Plausible Predictive and Diagnostic Markers**
Rajendra Prasad, PGIMER, Chandigarh, India

- P-01 **Identification and Functional Analysis of Choline Transporter in Tongue Cancer: A Novel Molecular Target for Tongue Cancer Therapy**
Ryohta Nishiyama, Tokyo Medical University, Japan
- P-02 **IL-1 β Induces Chemo Resistance to Cisplatin in Breast Cancer Cells Through Expression of Apoptosis-Evading Genes**
Monica Graciela Mendoza Rodr guez, Centro de Investigaci n y de Estudios Avanzados del Instituto Polit cnico Nacional, Mexico
- P-03 **Identification of a New Reactivator of Mutant P53 with *in vivo* Antitumor Activity**
Joana Oliveira Gama Soares, ICETA/REQUIMTE/FFUP, Portugal
- P-04 **Roy-Bz: A New Small-Molecule Selective Activator of Protein Kinase C δ with Anticancer Activity**
Cl udia Sofia Santos Bessa, ICETA/REQUIMTE/FFUP, Portugal
- P-05 **Atypical Antipsychotics for the Treatment of Brain Tumors**
Sarah Anne Samuels, University of Miami Brain Tumor Initiative, FL, USA
- P-06 **Cyclooxygenase-2 Regulates Tgf β -Induced Cancer Stemness in Triple-Negative Breast Cancer**
Jun Tian, McGill University, Canada
- P-07 **Dissecting the Role of Etv5 in Oligodendroglomagenesis**
Lata Adnani, University of Calgary, Canada
- P-08 **PEG Capped Methotrexate Silver Nanoparticles for Efficient Anticancer Activity and Biocompatibility**
Zarmina Muhammad, National University of Sciences and Technology, Pakistan
- P-09 **APOBEC3G Governs Cellular Oncogenic Transformation**
Anuradha Garg, PostGraduate Institute of Medical Education & Research, Chandigarh, India
- P-10 **Anti-inflammatory Effects of Novel 2,5-disubstituted-1,3,4-Oxadiazoles with Glycine/Alanine Hybrids**
Vijaya Rao Pidugu, Acharya Nagarjuna University, AP, India

	Cancer Stem Cell Therapy Treatment and Innovative Methods in Oncology Cancer Metabolic Reprogramming	Featured Presentations
Session Chairs	Philip Savage, Brighton and Sussex University Hospitals NHS Trust, UK Thomas Dirschka, Centroderm Clinic Wuppertal, Germany	
08:00-08:20	Biological Observations on the Chemotherapy Curable Malignancies: Unique Genetic Events, Frozen Development, Natural Apoptosis and Absent Cancer Stem Cells Philip Savage, Brighton and Sussex University Hospitals NHS Trust, UK	
08:20-08:40	New Targeted Treatments of Non-melanoma Skin Cancer Thomas Dirschka, Centroderm Clinic Wuppertal, Germany	
08:40-09:00	Inducing Differentiation of Premalignant Cells as a Novel Therapeutic Strategy in Hepatocarcinoma Uta Kossatz-Böhlert, University Hospital of Tuebingen, Germany	
09:00-09:20	Blocking Stem Cell Pathways Enhance Chemotherapeutic Sensitivity in Urothelial Cancer Mohammad Hoque, Johns Hopkins University School of Medicine, MD, USA	
09:20-09:40	Conditioned Medium from Adipose-Derived Stem Cells (ADSCs) Promotes Epithelial-to-Mesenchymal-Like Transition (EMT-Like) in Glioma Cells <i>in vitro</i> Marcia R. Wink, Cell Biology Lab, UFCSPA, Brazil	
09:40-10:00	Coffee Break	@ Chesapeake Foyer
10:00-10:20	Dissecting the Roles of Etv5 and Ascl1 in Oligodendrogliomagenesis Carol Schuurmans, University of Calgary, Canada	
10:20-10:40	Reirradiation in Recurrent Head and Neck Carcinomas: Why, When and How Anjali Kakria, Rajiv Gandhi Cancer Institute & Research Centre, Delhi, India	
10:40-11:00	Symbiotic Bacteria Provide Chemoprevention Against Hepatitis B Virus Mediated Hepatocellular Carcinoma in Hepatitis B x Transgenic Mice Mark Feitelson, Temple University, USA	
11:00-11:20	Next Generation Sequencing for Routine Clinical Tumor Genotyping: A Vital Link for Bench-to-Bedside Transition of Cancer Genomics Rajesh Singh, The University of Texas MD Anderson Cancer Center, TX, USA	
11:20-11:40	Mass Spectrometry-Based Proteomics: A Powerful Tool in Prostate Cancer Research Diego Iglesias Gato, University of Copenhagen, Denmark	
11:40-12:00	Repositioning for the Treatment of Thyroid Cancer Athanasios Bikas, MedStar Health Research Institute, MD, USA	

- 12:00-12:20 **Proteasome Inhibition in Cancer Treatment: Therapeutic Potentials and Side Effects**
Betul Karademir, Marmara University, Turkey
- 12:20-12:40 **Biological Implications of Targeting Fatty Acid Synthase in Breast Cancer**
Ruth Lupu, Mayo Clinic, Rochester, MN, USA
- 12:40-13:00 **Glycolytic Inhibition Modulates LD Biogenesis in Ovarian Cancer to Inhibit Cell Growth and Promotes Chemosensitivity**
Debarshi Roy, Mayo Clinic College of Medicine, Rochester, MN, USA
- 13:00-13:20 **Pemetrexed and Sorafenib Therapy: Now and the Future**
Paul Dent, Virginia Commonwealth University, VA, USA
- 13:20 **Lunch & Departures**

Notes

We wish to see you at
CRT-2017



2088 B2 Walsh Avenue, Santa Clara, CA 95050, USA

Ph: +1-408-426-4832, +1-408-426-4833; Toll Free: +1-844-395-4102; Fax: +1-408-426-4869

Email: cancer.therapy@uniscigroup.org

Web: www.unitedscientificgroup.com/conferences/crt-2016/